Journal of Antimicrobial Chemotherapy (2003) 51, ii17-ii25
© 2003 The British Society for Antimicrobial Chemotherapy
Supplement |
Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections
Bristol Centre for Antimicrobial Research and Evaluation, University of Bristol and North Bristol NHS Trust, Department of Medical Microbiology, Southmead Hospital, Westbury-on-Trym, Bristol BS10 5NB, UK
Abstract
The pharmacokinetics and pharmacodynamics of linezolid have been extensively investigated in laboratory models, healthy volunteers and patients. Three formulations exist: an intravenous (iv) form, film-coated tablets and an oral suspension. Linezolid can be assayed in serum and body fluids by HPLC and has good bioavailability with a Cmax at 0.5–2 h. The protein binding is 31%, and the volume of distribution is 30–50 L with adequate to good tissue penetration into skin blister fluids, bone, muscle, fat, alveolar cells, lung extracellular lining fluid and CSF. There are two major metabolites of linezolid (PNU-142586 and PNU-142300). Non-enzymic formation of PNU-142586 is the rate-limiting step in the clearance of linezolid, and linezolid and its two main metabolites plus several minor ones are all excreted in the urine. Dose linearity is evident in the Cmax and AUC across a wide range of doses. Gender and age have little effect on pharmacokinetics, but children have greater plasma clearance and volume of distribution and hence, have lower serum concentrations for equivalent doses in adults. No dose modification is needed in mild to moderate liver disease or any degree of renal impairment; however, both PNU-142586 and PNU-142300 accumulate in renal failure. Linezolid is bacteriostatic with a significant post-antibiotic effect against the key pathogens. In animal models of infection, the time the antibiotic concentration exceeds the MIC (t > MIC) helps to determine outcome, and a t > MIC of 40% is predictive of a bacteriostatic effect for both staphylococci and pneumococci. In man, t > MIC and AUC/MIC have been related to bacteriological and clinical outcomes. AUC and length of treatment are also related to the risk of thrombocytopenia.
Footnotes
* Tel: +44-117-959-5652; Fax: +44-117-959-3154; E-mail: alasdair.macgowan{at}north-bristol.swest.nhs.uk
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. J. Hilliard, J. Fernandez, J. Melton, M. J. Macielag, R. Goldschmidt, K. Bush, and D. Abbanat In Vivo Activity of the Pyrrolopyrazolyl-Substituted Oxazolidinone RWJ-416457 Antimicrob. Agents Chemother., May 1, 2009; 53(5): 2028 - 2033. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Pea, P. Viale, M. Lugano, U. Baccarani, F. Pavan, M. Tavio, G. L. Adani, G. Della Rocca, and M. Furlanut Biliary penetration and pharmacodynamic exposure of linezolid in liver transplant patients J. Antimicrob. Chemother., January 1, 2009; 63(1): 167 - 169. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Schmidt, R. Banks, V. Kumar, K. H. Rand, and H. Derendorf Clinical Microdialysis in Skin and Soft Tissues: An Update J. Clin. Pharmacol., March 1, 2008; 48(3): 351 - 364. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Steinkraus, R. White, and L. Friedrich Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001 05 J. Antimicrob. Chemother., October 1, 2007; 60(4): 788 - 794. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. E. Stein, S. Schooley, C. A. Peloquin, A. Missavage, and D. H. Havlichek Linezolid tissue penetration and serum activity against strains of methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility in diabetic patients with foot infections J. Antimicrob. Chemother., October 1, 2007; 60(4): 819 - 823. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Soriano, M. Ortega, S. Garcia, G. Penarroja, A. Bove, M. Marcos, J. C. Martinez, J. A. Martinez, and J. Mensa Comparative Study of the Effects of Pyridoxine, Rifampin, and Renal Function on Hematological Adverse Events Induced by Linezolid Antimicrob. Agents Chemother., July 1, 2007; 51(7): 2559 - 2563. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Myrianthefs, S. L. Markantonis, K. Vlachos, M. Anagnostaki, E. Boutzouka, D. Panidis, and G. Baltopoulos Serum and Cerebrospinal Fluid Concentrations of Linezolid in Neurosurgical Patients Antimicrob. Agents Chemother., December 1, 2006; 50(12): 3971 - 3976. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J I Prydal, D R Jenkins, A Lovering, and A Watts The pharmacokinetics of linezolid in the non-inflamed human eye Br J Ophthalmol, November 1, 2005; 89(11): 1418 - 1419. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Beringer, M. Nguyen, N. Hoem, S. Louie, M. Gill, M. Gurevitch, and A. Wong-Beringer Absolute Bioavailability and Pharmacokinetics of Linezolid in Hospitalized Patients Given Enteral Feedings Antimicrob. Agents Chemother., September 1, 2005; 49(9): 3676 - 3681. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Schriever, L. Zeitz-Colaizzi, A. Quinn, A. E. Schriever, and J. P. Cannon Considerations for the Management of Gram-Positive Pathogens in the Intensive Care Unit Journal of Pharmacy Practice, April 1, 2005; 18(2): 100 - 108. [Abstract] [PDF]
|
|
|
|
|
|
T. Whitehouse, J. A. Cepeda, R. Shulman, L. Aarons, R. Nalda-Molina, C. Tobin, A. MacGowan, S. Shaw, C. Kibbler, M. Singer, et al. Pharmacokinetic studies of linezolid and teicoplanin in the critically ill J. Antimicrob. Chemother., March 1, 2005; 55(3): 333 - 340. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Conte Jr., J. A. Golden, J. Kipps, M. McIver, and E. Zurlinden Intrapulmonary Pharmacokinetics and Pharmacodynamics of Itraconazole and 14-Hydroxyitraconazole at Steady State Antimicrob. Agents Chemother., October 1, 2004; 48(10): 3823 - 3827. [Abstract] [Full Text] [PDF]
|
|